IN8bio is a biotech company that develops gamma-delta T cell therapies for cancer treatment. The company's lead product candidates, INB-200 and INB-100, are in Phase I clinical trials for treating glioblastoma, solid tumors, and acute leukemia, respectively. IN8bio also has two preclinical products, INB-400 and INB-300, for treating solid tumor cancers.